Latest Headlines

1. ITOCHU Announces Strengthening Of Drug Development Support Through The Use Of AI-Driven Drug Discovery Technologies 10/7/2026

   ITOCHU Corporation (headquartered in Minato-ku, Tokyo; Keita Ishii, President & COO; hereinafter “ITOCHU”) announced today that it has signed a capital alliance agreement with MOLCURE Inc. (headquartered in Kawasaki City, Kanagawa Prefecture; Satoshi Tamaki, Representative Director, CEO & CSO; hereinafter “MOLCURE”), which possesses AI-driven drug discovery technologies for antibodies and peptides.

2. Carterra Advances Lab-In-The-Loop Drug Discovery Through New Scientific Collaboration 10/7/2026

   Carterra, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule drug discovery, today announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery

3. Nexentis: MitoCareX Bio Deploys Its Computational Drug Discovery Infrastructure On Google Cloud 10/7/2026

   Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform (“GCP”).

4. QIAGEN Expands AI-Powered Bioinformatics For Research And Drug Discovery 10/6/2026

   QIAGEN N.V. today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible.

5. Thermo Fisher Scientific Showcases New Solutions And Expanded Capabilities To Accelerate Drug Development At CPHI Milan 2026 10/6/2026

   Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum.

6. Mitsui Chemicals Launches InnoCell P-Type High Oxygen-Permeable Culture Plates To Accelerate Organoid-Based Drug Discovery 10/5/2026

   Mitsui Chemicals, Inc. (Tokyo; President & CEO: Satoshi Ichimura) has launched InnoCell P-Type, a new adherent cell culture plate in its InnoCell series of cell culture ware, as of October 1, 2026

7. Improving Vaccine Research Workflows Using Dependable Liquid Handling 10/2/2026

   The Wagner group at the University of Regensburg’s Institute of Medical Microbiology and Hygiene relies on liquid handling solutions from INTEGRA Biosciences to aid its vital research into molecular virology and vaccine development.

8. Streamlining Genotyping With The INTEGRA VOYAGER Pipette 10/2/2026

   The Robling Lab at Indiana University School of Medicine uses liquid handling solutions from INTEGRA Biosciences to aid its vital research into bone development and homeostasis.

9. Streamlining Cell Cultures With INTEGRA's VACUSAFE To Advance Respiratory Health Research 10/2/2026

   Researchers at the University of Technology Sydney (UTS), Australia, rely on the VACUBOY vacuum hand operator and VACUSAFE aspiration system from INTEGRA Biosciences to aid their research into respiratory health.

10. INTEGRA Clean-Up Week: Employees Send A Clear Signal For Sustainability And Responsibility 10/2/2026

    INTEGRA Biosciences carried out a cross-site Clean-Up Week in September 2026 at its main sites in Zizers, Switzerland, and Hudson/Merrimack, US. Over the course of a week, employees contributed to a more organized work environment, a more conscious use of resources, and a cleaner environment, both within the company and in the areas surrounding the sites.